# Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T

> **NCT02332902** · PHASE2 · COMPLETED · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 24 (actual)

## Conditions studied

- Neurofibromatosis 1

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT02332902
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02332902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02332902, "Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02332902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*